preventing the prejudicial effects provided by inter-individual differences and decreasing the number of participants needed to obtain appropriate statistical power), they also promote unsuspected carry-over effects which can negatively influence the confirmation of new treatments. Cross-over designs, therefore, may be designed to favor bias.
The problem: Placebo effects carry consequences
This tendency to favor bias was made obvious in a recent study published by Andre-Obadia and colleagues 1 . In their study, the authors used a double-blind, randomized, cross-over design to investigate the analgesic effects of repetitive transcranial magnetic stimulation (rTMS), and found that posteroanterior rTMS was more effective than sham and/or lateromedial rTMS. Interestingly, the authors observed that the analgesic effects induced by posteroanterior rTMS were easier to demonstrate when compared with lateromedial rTMS than when compared with sham-rTMS. This observation led Andre-Obadia et al. to conduct a second study in which they specifically evaluated sequence effects (i.e., pertaining to the timing of the different interventions within the protocol) 2 . They found that the sham intervention significantly decreased pain when it followed a successful rTMS session. On the other hand, there was a tendency for sham-rTMS to increase pain when it followed an unsuccessful rTMS session. Only when the sham intervention was applied first did it provide scores that were
Reassessing randomized clinical trials 4 comparable to baseline (i.e., no intervention at all). Taken together, these observations indicate that the efficacy of past treatments can have a major impact on the efficacy of future treatments, even when these future treatments are designed as inactive controls. This means that placebo interventions may not be, and perhaps have never been, valid control conditions in randomized crossover trials.
From a theoretical perspective, the observations of Andre-Obadia et al. 2 can be explained by the conditioning model of placebo analgesia 3 . According to classical conditioning theory, the repeated experience of an effective analgesic treatment (the unconditioned stimulus) facilitates the development of robust associations between active treatment effects (in this case active rTMS-induced analgesia) and the surrounding environment (laboratory, rTMS coil, experimenter, etc.). Once the conditioning phase is over, simply presenting the neutral stimulus can produce the unconditioned response, even in the absence of active ingredients. Although this issue is still debated in the field, it is generally admitted that the conditioning effect for pain and other conscious processes relies heavily on expectations created during the conditioning phase 4 . A few reviews address the influence of expectations, conditioning, and, other confirmatory phenomena in placebo studies 3, [5] [6] [7] . However, regardless of the variables which may affect placebo and placebo-like phenomena, it is important to point out that, in clinical trials, pre-crossover conditions may very well produce conditioned responses which can affect post-crossover conditions.
Of course, conditioned responses are not limited to placebo or sham conditions, but may also affect active treatments. Thus, given the right circumstance, it may be possible to kill the efficacy of valid treatments. We recently observed this phenomenon in a study designed to investigate the involvement of endogenous opioids in high-frequency TENS analgesia 8 . Specifically, we found that when TENS was first experienced as ineffective (because of opioid blockade with naloxone) the analgesic effect of all subsequent TENS treatments were completely blocked, even though naloxone was never again provided. Had sequence effects been ignored, we would have erroneously concluded
Reassessing randomized clinical trials 5 that high-frequencey TENS was not opioidergic. In our study participants never experienced TENS prior to their participation. This is worth mentioning because prior experience of the treatment at hand might have influenced treatment efficacy during the first condition, and thus, might have further influenced carry-over effects. Given this possibility, it is always a good idea to take prior treatment experiences into consideration before conducting clinical trials.
The study of Andre-Obadia et al. 2 and our study 8 conducting cross-over designs) 9, 10 , the results obtained from cross-over designs need to be interpreted cautiously, and perhaps even questioned outright. In particular, the present studies constitute eloquent examples of why crossover designs run the risk of providing false negatives, either because placebo controls become active and thus hard to beat or because active treatments are rendered completely ineffective. We wish to point out here that it may still be possible for new treatments to survive the biasing effects inherent to cross-over designs, and thus outperform shams. When this happens, researchers can be quite sure that the new treatment they are investigating is truly potent.
Unfortunately, short of being extremely potent, many new (and effective) drugs may not survive the biasing effects of carry-over, and thus be cavalierly dismissed.
 Treatment failure in our study was caused by the use of naloxone, which provoked a strong abolition of analgesia. On the other hand, treatment failure in conventional clinical trials is typically caused by the use of an inactive substance (i.e., a placebo), which likely provokes a milder degree of treatment failure. As a result, researchers can probably expect weaker negative carry-over effects than ours when running conventional clinical trials. Nevertheless, negative carry-over effects remain a very real possibility; even in placebo-controlled cross-over trials.
Decaying treatment effects may be the solution
In their paper, Andre-Obadia et al. 2 We propose an alternative solution, based on the observations made a number of years ago by
Fedele and colleagues 11 . In their study, the authors noted a positive treatment effect during placebo trials which, interestingly, disappeared progressively following repeat exposures to placebos 11, 12 . Sadly treatments over time, as described in Table 1 . This would allow researchers (1) to document and study resistance to extinction, a property of active but not placebo treatments, and, (2) to identify the appropriate time point to use when comparing active and placebo treatments.
Evidently, the solution we propose has the disadvantage of increasing the cost and duration of clinical trials. We nevertheless believe this to be necessary in order to ensure the validity of results obtained from cross-over designs. The time needed for conditioning and/or expectation effects to
Reassessing randomized clinical trials 7 extinguish remains uncertain, and likely to vary as a function of conditioned effects. Clearly, future studies are needed to evaluate the time needed for conditioning and/or expectation effects to extinguish, and, to study the impact this may have on the running of clinical trials.
Conclusion
In conclusion, the study of Andre-Obadia et al. 2 and the study of Leonard et al. 8 illustrate that the results of cross-over designs need to be interpreted cautiously. The reader must also acknowledge that sequence effects do not only affect pain research. Indeed, placebo effects are observed in a wide variety of other conditions and treatments 13 , making it probable that sequence effects are also present in cross-over designs aimed at evaluating the efficacy of treatments in other health conditions. The use of cross-over designs that include measurements at multiple time points represent, in our view, a viable solution for researchers who wish to continue using cross-over designs, but who do not want to run the risk of erroneously shelving promising new treatments. The field is ready for novel research studies and targeted review papers on this potentially influential issue. 
